The effects of preoperative 18F-FDG PET/CT in breast cancer patients in comparison to the conventional imaging study

Journal of Breast Cancer

Volumn 15, Issue 4, 2012, Pages 441-448

  Choi, Young Jin ^a   Shin, Young Duck ^b   Kang, Yoon Hee ^a   Lee, Moon Soo ^a   Lee, Min Koo ^a   Cho, Byung Sun ^a   Kang, Yoon Jung ^a   Seung Park, Ju ^a  

^a Eulji University School of Medicine   (South Korea)

^b Chungbuk National University Hospital   (South Korea)

Author keywords

Breast; Carcinoma; Computed tomography; Diagnostic imaging; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; BREAST BIOPSY; BREAST CANCER; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; ECHOMAMMOGRAPHY; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; TUMOR VOLUME;

EID: 84872314152     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2012.15.4.441     Document Type: Article

References (23)

1. Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001;19:3516-23.
2. Fehr MK, Hornung R, Varga Z, Burger D, Hess T, Haller U, et al. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 2004;10:89-93.
3. Jacobs MA, Ouwerkerk R, Wolff AC, Gabrielson E, Warzecha H, Jeter S, et al. Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat 2011;128:119-26.
4. Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess 2010;14:1-103.
5. Kumar R, Zhuang H, Schnall M, Conant E, Damia S, Weinstein S, et al. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 2006;27:231-6.
6. Zornoza G, Garcia-Velloso MJ, Sola J, Regueira FM, Pina L, Beorlegui C. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 2004;30:15-9.
7. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002; 128:325-8.
8. Ueda S, Saeki T, Shigekawa T, Omata J, Moriya T, Yamamoto J, et al. 18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol 2012;17:276-82.
9. Segaert I, Mottaghy F, Ceyssens S, De Wever W, Stroobants S, Van Ongeval C, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J 2010;16:617-24.
10. Inokuchi M, Furukawa H, Kayahara M, Ohta T, Kawashima H, Taki J, et al. The role of /18FDG PET/CT for the initial staging and therapy in primary breast cancer. Gan To Kagaku Ryoho 2009;36:2526-31.
11. Bombardieri E, Crippa F. PET imaging in breast cancer. Q J Nucl Med 2001;45:245-56.
12. Garami Z, Hascsi Z, Varga J, Dinya T, Tanyi M, Garai I, et al. The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan. Eur J Surg Oncol 2012;38:31-7.
13. Danforth DN Jr, Aloj L, Carrasquillo JA, Bacharach SL, Chow C, Zujewski J, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002;75:135-46.
14. Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007; 18:473-8.
15. Robertson IJ, Hand F, Kell MR. FDG-PET/CT in the staging of local/ regional metastases in breast cancer. Breast 2011;20:491-4.
16. Heusner TA, Freudenberg LS, Kuehl H, Hauth EA, Veit-Haibach P, Forsting M, et al. Whole-body PET/CT-mammography for staging breast cancer: initial results. Br J Radiol 2008;81:743-8.
17. Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T, et al. Preoperative PET/CT in early-stage breast cancer. Ann Oncol 2012;23:2277-82.
18. Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaria G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008; 26:4746-51.
19. Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med2004;45:266-71.
20. Liu Y. Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls. Ann Nucl Med 2009;23:107-12.
21. Alkhawaldeh K, Bural G, Kumar R, Alavi A. Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 2008;35:246-52.
22. Kumar R, Halanaik D, Malhotra A. Clinical applications of positron emission tomography-computed tomography in oncology. Indian J Cancer 2010;47:100-19.
23. Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 2001;22:875-9.